KLUS Pharma to attend 14th World ADC London 2024

KLUS Pharma will attend the 14th World ADC conference held in London, UK from March 12-15, 2024. KLUS Pharma is the US subsidiary of Kelun-Biotech, a mid-sized innovative biopharma company based in Chengdu, China. Kelun-Biotech is advancing a robust pipeline of innovative antibody drug conjugates (ADCs) for the treatment of solid tumor indications, based on its proprietary ADC platform (OptiDC) utilizing a novel TOP1 payload and optimized linkers. Several of these ADCs have advanced into clinical trials, including TROP2, Claudin 18.2, and Nectin-4, with multiple other candidates in preclinical development. Additionally, in ongoing collaboration with MSD, the global development and commercial strategy for certain ADC assets are underway. Kelun-Biotech is committed to becoming a leader in the ADC field and welcomes the opportunity to collaborate with potential partners to develop safer and more efficacious ADCs for the treatment of cancer and other serious diseases.